Evidence map›Paper›PMID 22545163›Full record

ReviewPLoS neglected tropical diseases2012

A research agenda for helminth diseases of humans: intervention for control and elimination.

Roger K Prichard, María-Gloria Basáñez, Boakye A Boatin, James S McCarthy, Héctor H García, Guo-Jing Yang, Banchob Sripa, Sara Lustigman

Open access · goldAbstract readReview
In one paragraph

Review in PLoS neglected tropical diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 4 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 4 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Anti-filarial efficacy ofRSC advances · 2024
    Article
  13. Article
  14. Role of cytokines in immunomodulation during malaria clearance.Annals of medicine and surgery (2012) · 2024
    Review
  15. Article
  16. Article
  17. Paragonimiasis.Advances in experimental medicine and biology · 2024
    Review
  18. Review
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 8 countries.

Roger K PrichardInstitute of Parasitology, McGill University, Montreal, Canada. roger.prichard@mcgill.ca
María-Gloria Basáñez
Boakye A Boatin
James S McCarthy
Héctor H García
Guo-Jing Yang
Banchob Sripa
Sara Lustigman
Imperial College London · GBJiangsu Institute of Parasitic Diseases · CNKhon Kaen University · THMcGill University · CANew York Blood Center · USUniversidad Peruana Cayetano Heredia · PEUniversity of Ghana · GHUniversity of Queensland · AU

Funding

The development of a recombinant vaccine against human onchocerciasisR01AI078314 · NIAID · NEW YORK BLOOD CENTER · PI LUSTIGMAN, SARA · 2009 to 2021
$7.0M
Pathogenesis of Liver Fluke Induced Cancer in ThailandU01AI065871 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI BRINDLEY, PAUL J · 2005 to 2009
$3.5M
NIAID NIH HHS R01 AI078314NIAID NIH HHS R01AI078314NIAID NIH HHS U01 AI065871NIAID NIH HHS U01AI065871Wellcome Trust 085133/Z/08/ZWellcome Trust 091077Wellcome Trust 092677/Z/10/Z
6 · The paper itself

Abstract

Recognising the burden helminth infections impose on human populations, and particularly the poor, major intervention programmes have been launched to control onchocerciasis, lymphatic filariasis, soil-transmitted helminthiases, schistosomiasis, and cysticercosis. The Disease Reference Group on Helminth Infections (DRG4), established in 2009 by the Special Programme for Research and Training in Tropical Diseases (TDR), was given the mandate to review helminthiases research and identify research priorities and gaps. A summary of current helminth control initiatives is presented and available tools are described. Most of these programmes are highly dependent on mass drug administration (MDA) of anthelmintic drugs (donated or available at low cost) and require annual or biannual treatment of large numbers of at-risk populations, over prolonged periods of time. The continuation of prolonged MDA with a limited number of anthelmintics greatly increases the probability that drug resistance will develop, which would raise serious problems for continuation of control and the achievement of elimination. Most initiatives have focussed on a single type of helminth infection, but recognition of co-endemicity and polyparasitism is leading to more integration of control. An understanding of the implications of control integration for implementation, treatment coverage, combination of pharmaceuticals, and monitoring is needed. To achieve the goals of morbidity reduction or elimination of infection, novel tools need to be developed, including more efficacious drugs, vaccines, and/or antivectorial agents, new diagnostics for infection and assessment of drug efficacy, and markers for possible anthelmintic resistance. In addition, there is a need for the development of new formulations of some existing anthelmintics (e.g., paediatric formulations). To achieve ultimate elimination of helminth parasites, treatments for the above mentioned helminthiases, and for taeniasis and food-borne trematodiases, will need to be integrated with monitoring, education, sanitation, access to health services, and where appropriate, vector control or reduction of the parasite reservoir in alternative hosts. Based on an analysis of current knowledge gaps and identification of priorities, a research and development agenda for intervention tools considered necessary for control and elimination of human helminthiases is presented, and the challenges to be confronted are discussed.

Indexed as

AnimalsAnthelminticsCommunicable Disease ControlDrug DiscoveryDrug ResistanceDrug TherapyEducation, MedicalHelminthiasisHelminthsHumansAnthelmintics

Identifiers

PMID22545163
PMCPMC3335868
OpenAlexW2002202509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.